-
-
-
-
-
-
-
UBS Upgrades Jazz Pharmaceuticals (JAZZ) to Buy
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
-
-
-
-
-
-
JAZZ (JAZZ) to Acquire Chimerix (CMRX) for $8.55/sh Cash
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Reports Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 22c; Lowers Outlook
-
15,739 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

